UBS raised the firm’s price target on Edwards Lifesciences to $92 from $84 and keeps a Neutral rating on the shares. Edwards Lifesciences’ results were broadly in line with expectations, and the firm came away from the call with little to either shake confidence in the company’s ability to achieve its current 8%-10% global TAVR sales growth guidance in 2024 or instill increasing conviction that there’s meaningful potential upside to 2024 total sales or EPS guidance, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
